Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Top Five Insights from the IQVIA Institute 2019 Oncology Trends Report
Michael Kleinrock, Director, Research Development, IQVIA Institute for Human Data Science
Sep 30, 2019
  • Blogs
  • Top Five Insights from the IQVIA Institute 2019 Oncology Trends Report

Our Global Oncology Trends 2019 report is officially released, and it details the trends shaping the development and delivery of cancer treatment worldwide. 

I’d like to share with you five key insights from the report. For all of the detailed, data-driven insights, download the full report and explore the trends influencing clinical development in oncology treatments today and through 2023. 

  1. Immunotherapies are rapidly being adopted as first-line treatments

    2. Cancer patients today have more and better treatment options than ever, with improvements in progression-free survival and new options for relapsed or refractory cancers. Immuno-oncology therapies account for many of the new options and have in just 2-3 years become first-line oncology treatments (see exhibit). 

    These treatments now account for more than three-quarters of all lines of therapy in metastatic melanoma.

    Similarly, treatment for breast cancer, the most prevalent cancer among women, has been transformed with the introduction and rapid uptake of new options, particularly CDK4/6 inhibitors. The number of patients treated with these drugs nearly tripled in the top five European countries in the past year, now matching similar rates of use in the U.S. 

  2. Precision medicine and biomarkers increase trial complexity

    3. Precision medicines stratify patients according to their biomarkers into those most likely to respond to therapy, for both trials and treatment. Predictive biomarkers were associated with 60% of new treatments, and three were approved with a companion diagnostic. 

    Biomarker testing for trials is becoming easier and more widely available, improving the selection of trial participants. Nonetheless, trial complexity may increase as novel trial designs are enabled (i.e. large basket trials with multiple arms) and as sponsors become reliant on molecular profiling companies for data.

  3. Spending growth continues in double digits

    4. Driving the increase in health-system spending is not only the use of new treatments, but also the use of available treatments in more patients and for longer treatment durations. Spending levels and growth rates are higher across most parts of the world, and this is expected to continue for at least the next five years. New and protected brands account for nearly all the growth in spending. 

    Spending on cancer drugs in the U.S. has more than doubled since 2013 and reached almost $57 billion in 2018. Outside the U.S., oncology costs exceeded $66 billion in 2018, driven by new product launches and increased volume use of existing brands.

  4. Time to approval is decreasing, but delivery remains a barrier

    5. New oncology drugs launched in 2018 went from patent filing to approval four years more quickly than drugs launched in 2017. But more than half of new cancer treatments are available only within a select nine countries, and novel therapies such as CAR-T require capabilities that are rare even in the U.S. 

    For example, CAR-T cancer treatments require that centers be competent to collect T cells and reintroduce them to the patient. Few cancer centers have achieved accreditation, and these centers can be thousands of miles away from a patient. In France, a 2016 study found that only eight hospitals, treating 11% of patients, met the criteria (see exhibit).

    The difficulties in accessing these new treatments can place logistical and financial burdens on families and caregivers. However, because treatment time can be shorter, the total burden doesn’t necessarily increase but is borne over a shorter time period. 

  5. Trial productivity is key in this high risk, high reward therapy area

    6. Overall productivity of oncology trials has improved since 2000 by 22% but remains far lower than trials for other therapy areas. Researchers are improving the productivity of trials by identifying participants from pools of pre-screened patients, which could improve productivity 104% by 2023. The use of biomarker tests is projected to yield a 71% improvement. 

    The following exhibit shows the possible impact of the top eight oncology trends on trial productivity over the next five years. The likely impact of each trend is detailed in the full report. 

A closer look at oncology trends

The full report –  Global Oncology Trends 2019 – is rich with data and exhibits illuminating the trends influencing clinical development in oncology treatments today and through 2023, including scientific advances in therapeutics, shifts in therapy use, trial productivity and success rates, as well as changes in spending patterns. I invite you to download it today, along with the full set of exhibits you can reference in your own work.

Contact Us